Valuation: Immuno-Biological Laboratories Co., Ltd.

Market Cap 10.92B 69.37M 61.61M 57.62M 52.5M 98.85M 6.68B 100M 697M 270M 3.4B 260M 255M P/E 2025
18x
P/E 2026 38x
Enterprise Value 10.11B 64.2M 57.03M 53.33M 48.6M 91.49M 6.18B 92.75M 645M 250M 3.15B 241M 236M EV / Sales 2025
3.97x
EV / Sales 2026 11.6x
Free-Float
82.46%
Yield 2025 *
-
Yield 2026 0.45%
23-05-12 Immuno-Biological Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
23-02-05 An unknown buyer agreed to acquire unknown minority stake in CURED Co., Ltd. from Immuno-Biological Laboratories Co., Ltd. CI
19-12-19 An undisclosed buyer acquired 26.32% stake in Cell Remover Co., Ltd. from Immuno-Biological Laboratories Co., Ltd.. CI
19-03-28 CURED Co., Ltd. announced that it has received ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
19-02-26 CURED Co., Ltd. announced that it expects to receive ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
18-11-14 Neo Silk Cosmetics Co., Ltd. announced that it has received ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
18-11-04 Neo Silk Cosmetics Co., Ltd announced that it expects to receive ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
17-06-27 Transgenic Inc. Enters into Joint Research Agreement with Immuno-Biological Laboratories Co. Ltd CI
16-12-19 Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥1.4 billion in funding from Whiz Partners Inc. CI
16-11-30 Immuno-Biological Laboratories Co., Ltd. announced that it expects to receive ¥1.39 billion in funding from Whiz Partners Inc. CI
16-05-10 CURED Co., Ltd. announced that it has received ¥159.6 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd. CI
16-04-19 CURED announced that it expects to receive ¥159.6 million in funding from Trans Genic Inc. and Immuno-Biological Laboratories Co., Ltd. CI
16-03-30 Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it has received ¥100 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd. CI
1 day-1.02%
1 week-4.05%
Current month-3.17%
1 month+12.72%
3 months+18.95%
6 months-15.38%
Current year-38.73%
1 week 1,141
Extreme 1141
1,219
1 month 1,021
Extreme 1021
1,225
Current year 888
Extreme 888
2,025
1 year 464
Extreme 464
3,820
3 years 356
Extreme 356
3,820
5 years 285
Extreme 285
3,820
10 years 285
Extreme 285
3,820
Manager TitleAgeSince
President 82 1982-08-31
Director of Finance/CFO 64 2008-03-31
Chief Administrative Officer 65 2004-05-31
Director TitleAgeSince
Director/Board Member 82 1982-08-31
Director/Board Member 64 2008-05-31
Director/Board Member 65 2001-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-4.05%+149.68%+111.09% 71.06M
-0.62%-2.71%+39.30%+114.07% 1,031B
-2.30%-4.44%+39.03%+66.07% 638B
-0.63%-1.96%+6.36%+74.38% 462B
-1.03%-2.82%+59.56%+39.69% 359B
-0.03%-3.96%+23.63%+39.35% 335B
-1.58%-0.76%+13.50%+25.77% 273B
-2.02%-2.97%-3.25%+8.38% 253B
-3.38%+0.30%+36.44%+51.54% 228B
-1.04%-1.46%+32.70%+96.82% 185B
Average -1.37%-1.31%+39.69%+62.72% 376.39B
Weighted average by Cap. -1.25%-1.89%+30.52%+69.18%

Financials

2025 2026
Net sales 969M 6.15M 5.46M 5.11M 4.66M 8.77M 592M 8.89M 61.82M 23.93M 302M 23.1M 22.6M 1B 6.37M 5.66M 5.3M 4.83M 9.08M 614M 9.21M 64.06M 24.8M 313M 23.93M 23.42M
Net income 249M 1.58M 1.4M 1.31M 1.2M 2.25M 152M 2.28M 15.89M 6.15M 77.52M 5.94M 5.81M 329M 2.09M 1.86M 1.74M 1.58M 2.98M 201M 3.02M 20.99M 8.13M 102M 7.84M 7.67M
Net Debt -621M -3.94M -3.5M -3.28M -2.98M -5.62M -380M -5.7M -39.62M -15.34M -193M -14.8M -14.48M -813M -5.16M -4.58M -4.29M -3.91M -7.36M -497M -7.46M -51.87M -20.08M -253M -19.38M -18.96M
Logo Immuno-Biological Laboratories Co., Ltd.
Immuno-Biological Laboratories Co., Ltd. is a Japan-based company engaged in the research, development, manufacture and sales of pharmaceutical products and quasi-drugs. The Company operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
Employees
54
Date Price Change Volume
26-10-01 JP¥1,161.00 -1.02% 37,900
26-10-01 JP¥1,173.00 -2.17% 118,000
26-09-30 JP¥1,199.00 +3.81% 122,800
26-09-29 JP¥1,155.00 -1.03% 72,700
26-09-28 JP¥1,167.00 -3.55% 130,200

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4570 Stock